This project aims to investigate the anticancer activity of the MDM2 inhibitor, nutlin-3a, in the treatment of retinoblastoma using both conventional 2D in vitro models and more-realistic 3D-bioprinted models. Here, MDM2 is linked to retinoblastoma.